Pharmacokinetic interactions between etravirine and non-antiretroviral drugs

Clinical Pharmacokinetics

Volumn 50, Issue 1, 2011, Pages 25-39

  Kakuda, Thomas N ^a   Schöller Gyüre, Monika ^b   Hoetelmans, Richard M W ^b  

^a Tibotec Inc   (United States)

^b TIBOTEC BVBA   (Belgium)

Author keywords

Anti infectives, drug interactions; Antidepressants, drug interactions; Antiepileptic drugs, drug interactions; Antifungals, drug interactions; Antiretrovirals, drug interactions; Atorvastatin, drug interactions; Azithromycin, drug interactions; Buprenorphine, drug interactions; Calcineurin inhibitors, drug interactions; Clarithromycin, drug interactions; Corticosteroids, drug interactions; Dexamethasone, drug interactions; Diazepam, drug interactions; Digoxin, drug interactions; Drug interactions; Ethinylestradiolnorethisterone, drug interactions; Etravirine, drug interactions; Fibric acid derivatives, drug interactions; Fluconazole, drug interactions; Fluoxetine, drug interactions; Fluvastatin, drug interactions; Histamine H2 receptor antagonists, drug interactions; HMG CoA reductase inhibitors, drug interactions; Hypericum, drug interactions; Itraconazole, drug interactions; Ketoconazole, drug interactions; Methadone, drug interactions; Non nucleoside reverse transcriptase inhibitors, drug interactions; Omeprazole, drug interactions; Opioid analgesics, drug interactions; Oral contraceptives, drug interactions; Paroxetine, drug interactions; Pharmacokinetics; Proton pump inhibitors, drug interactions; Ranitidine, drug interactions; Ribavirin, drug interactions; Rifabutin, drug interactions; Rifampicin, drug interactions; Rifapentine, drug interactions; Rosuvastatin, drug interactions; Sertraline, drug interactions; Sildenafil, drug interactions; Simvastatin, drug interactions; Type 5 cyclic nucleotide phosphodiesterase inhibitors, drug interactions; Voriconazole, drug interactions; Warfarin, drug interactions

Indexed keywords

ATORVASTATIN; AZITHROMYCIN; CARBAMAZEPINE; CITALOPRAM; CLARITHROMYCIN; CLOPIDOGREL; CYCLOSPORIN A; CYTOCHROME P450 2C; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DEXAMETHASONE; DIAZEPAM; DIGOXIN; ETHINYLESTRADIOL; ETRAVIRINE; FLUCONAZOLE; HYPERICUM PERFORATUM EXTRACT; METHADONE; NORETHISTERONE; OMEPRAZOLE; PAROXETINE; PHENYTOIN; RANITIDINE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SILDENAFIL; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

BACTERIAL INFECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 78649971748     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11534740-000000000-00000     Document Type: Review

References (54)

1. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleo-side reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-6.
2. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
3. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
4. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled week 48 analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
5. Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010; 15 (7): 1045-52.
6. Scholler-Gyure M, Kakuda TN, Raoof A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009; 48: 561-74.
7. Kakuda TN, Scholler-Gyure M, Workman C, et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther 2008; 13: 655-61.
8. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of dar- unavir/ritonavir and TMC125 alone and co-administered in HIV-negative volunteers. Antivir Ther 2007; 12: 798-806.
9. Data on file, Tibotec Pharmaceuticals, 2005.
10. Kakuda TN, Scholler-Gyure M, De Smedt G, et al. Assessment of the steady- state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med 2009; 10: 173-81.
11. Kakuda TN, Scholler-Gyure M. Design of antiretroviral drug interaction studies. Curr Opin HIV AIDS 2008; 3: 313-8.
12. Scholler-Gyure M, Woodfall B, Debroye C, et al. Pharmacokinetic interaction between TMC125 and rifabutin [poster no. 1059]. 44th Annual Meeting of the Infectious Diseases Society of America; 2006 Oct 12-15; Toronto (ON).
13. Scholler-Gyure M, Debroye C, Woodfall B, et al. Pharmacokinetic interaction between TMC125 and clarithromycin [poster no. 1351]. 44th Annual Meeting of the Infectious Diseases Society of America; 2006 Oct 12-15; Toronto (ON).
14. Scholler-Gyure M, Kakuda TN, Van Solingen-Ristea R, et al. Pharmaco- kinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers [poster no. A1-1299]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2009 Sept 12-15; San Francisco (CA).
15. Scholler-Gyure M, van den Brink W, Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008; 48: 322-9.
16. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol 2008; 66: 508-16.
17. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and atorvastatin in HIV-negative volunteers [poster no. WEPEA106]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney (NSW).
18. Scholler-Gyure M, Kakuda TN, Woodfall B, et al. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestra-diol and norethindrone. Contraception 2009; 80: 44-52.
19. Scholler-Gyure M, Kakuda TN, Bollen S, et al. No pharmacokinetic inter- action between TMC125 (etravirine; ETR) and paroxetine in HIV-negative volunteers [poster no. P4.3/01]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid.
20. Scholler-Gyure M, Debroye C, Vyncke V, et al. Effect of TMC125 on sildenafil pharmacokinetics [poster no. 45]. 7th International Workshop of Clinical Pharmacology of HIV therapy; 2006 Apr 20-22; Lisbon.
21. Scholler-Gyure M, Kakuda TN, Van Solingen-Ristea RM, et al. No clinically relevant effect of etravirine (ETR; TMC125) on digoxin pharmacokinetics in HIV-negative volunteers [poster no. P22]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 2008 Apr 7-9; New Orleans (LA).
22. Kakuda TN, Scholler-Gyure M, Hoetelmans RMW. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse tran-scriptase inhibitor etravirine. Antivir Ther 2010; 15 (6): 817-29.
23. Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmaco- dynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther 2010; 88 (5): 695-703.
24. Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 2004; 4 (9): 557-65.
25. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
26. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000; 34: 495-513.
27. Inderlied CB, Sandoval FG, Young SL. In vitro activity of clarithromycin (CLARI) and 14-hydroxy-clarithromycin against Mycobacterium avium complex (MAC) alone andincombination with other agents [abstractno239]. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1991 Sep 29-Oct 2; Chicago (IL).
28. Hofmann WP, Herrmann E, Sarrazin C, et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back tomolecular mechanisms. Liver Int 2008; 28: 1332-43.
29. Dodds-Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic anti- fungal agents. Clin Infect Dis 2006; 43: S28-39.
30. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005; 6: 2231-43.
31. Ferrari A, Coccia CP, Bertolini A, et al. Methadone - metabolism, pharma- cokinetics and interactions. Pharmacol Res 2004; 50: 551-9.
32. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999; 47: 403-12.
33. Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78: 593-604.
34. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N- dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998; 26: 818-21.
35. Bruce RD, McCance-Katz E, Kharasch ED, et al. Pharmacokinetic interac- tions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43 Suppl. 4: S216-23.
36. Krikorian SA, Rudorf DC. Drug-drug interactions and HIV therapy: what should pharmacists know? J Pharm Pract 2005; 18: 278-94.
37. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008; 47 (2): 75-89.
38. Tomlinson ES, Lewis DF, Maggs JL, et al. In vitro metabolism of dexa- methasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol 1997; 54: 605-11.
39. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorph- isms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
40. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-81.
41. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34: 155-62.
42. Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Exp Opin Drug Metab Toxicol 2007; 3 (3): 441-50.
43. Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive ste- roids: an update. Clin Pharmacokinet 1991; 20: 15-37.
44. Palovaara S, Tybring G, Laine K. The effect of ethinyloestradiol and levo- norgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol 2003; 56: 232-7.
45. Shelepova T, Nafziger AN, Victory J, et al. Effect of a triphasic oral contra- ceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 2005; 45: 1413-21.
46. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30: 1206-27.
47. Mehrotra N, Gupta M, Kovar A, et al. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007; 19: 253-64.
48. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2005; 61 (3): 246-55.
49. Christian H, Bertera FM, Mayer MA, et al. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol 2010; 6 (2): 199-211.
50. Ha HR, Follath F. Metabolism of antiarrhythmics. Curr Drug Metab 2004; 5 (6): 543-71.
51. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-42.
52. Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol 2008; (182): 335-60.
53. Scholler-Gyure M, Kakuda TN, Stevens T, et al. Effect of etravirine on cyto- chrome P450 isozymes assessed by the Cooperstown 5+1 cocktail [poster no. 955]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2008 Oct 25-28; Washington, DC.
54. Hafner V, Jager M, Matthee AK, et al. Effect of simultaneous induction and inhibition of CYP3Aby St John's wort and ritonavir on CYP3A activity. Clin Pharmacol Ther 2010; 87: 191-6